engleski

Virtual follow-up of a patient with type 1 diabetes during quarantine due to COVID-19

Virtual follow-up of a patient with type 1 diabetes during quarantine due to COVID-19 Leon Perić1 ; Barbara Bačun2, Ivo Vincetić1 ; Ena Botić1 ; Dunja Degmečić1, 3 ; Tatjana Bačun1, 4 1 – Faculty of Medicine Osijek, University of J.J. Strossmayer, Osijek, Croatia 2 – Faculty of Dental Medicine and Health, Unversity of J.J. Strossmayer, Osijek, Croatia 3 – Clinical Hospital Centre, Department of Psychiatry, Osijek, Croatia 4 – Clinical Hospital Centre, Department of Internal Medicine, Osijek, Croatia Introduction: ''Flash glucose monitoring'' system that measures glucose in intracellular fluid is an easy way to self-monitor to get a complete picture of glycemia. Connecting to the LibreView platform provides a ''cloud-based'' diabetes monitoring tool that allows physicians and patients to analyze data through glucose movement reports and to optimize therapy. Case report: Hereby we report a case of a 29-year- old patient who was diagnosed with type 1 diabetes at the age of 12. The patient receives long-acting insulin detemir, 12 U at 10 a.m. and 10 p.m. and short acting pre-meal insulin aspart, depending on glycemic values and carbohydrate unites in the meal. Considering she is planning a pregnancy, the long- acting insulin degludec was replaced with detemir one month ago. Since then, she had oscillating glycemic values. The patient was placed in quarantine for 21 days due to positive PCR test for SARS-CoV-2. The LibreView glycemic monitoring platform provided regular monitoring of the patient and insight into the patient's glycemic profile during self-isolation. The average glycemic value for the previous 14 days was 9.0 mmol/L and the estimated glycated hemoglobin was 7.2%. Only 66% of the time, the glycemia was within the target values of glycemia. Additional education of the patient was conducted through telephone conversation. It is planned to administer insulin preconception via insulin pump and until then monitor glycemic levels via virtual clinic. Conclusion: The application of new technologies for continuous glucose monitoring and telemedicine monitoring has simplified the treatment of patients with diabetes during COVID-19 pandemic.

glucose monitoring, telemedicine, type 1 diabetes mellitus, quarantine, COVID-19

nije evidentirano